J&J's pancreatic-enzyme treatment Pancreaze gains FDA approval

04/12/2010 | Reuters

The FDA approved Pancreaze for use in patients with cystic fibrosis and other conditions caused by pancreatic-enzyme deficiency. The treatment, developed by Johnson & Johnson, will compete with pancreatic-enzyme products from Eurand and Abbott Laboratories.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC